Skip to main content

Determination of Idarubicin Using CdTe Quantum Dots as Fluorescence Probes

Buy Article:

$107.14 + tax (Refund Policy)

A simple and fast method for the determination of Idarubicin (IDA) was developed based on the fluorescence quenching effect of IDA for 3-mercaptopropionic acid—capped CdTe quantum dots. Under optimum conditions, the calibration plot of F 0 /F versus the concentration of IDA was linear in the range of 1–200 μM with correlation coefficient of 0.9969. The limit of detection was 0.2 μM. The recoveries of IDA standard solution spiked with sample were in the range of 99.75–100.9% with the relative standard deviations less than 5.0%. The method was applied to the determination of IDA in its commercial powder-injection sample and the result agreed with the claimed values. The mechanism of the fluorescence quenching was discussed.

Keywords: CdTe Quantum Dots; Fluorescence Probe; Idarubicin

Document Type: Research Article

Affiliations: Gansu Provincial Hospital, Lanzhou 730000, China

Publication date: 01 July 2016

More about this publication?
  • Journal for Nanoscience and Nanotechnology (JNN) is an international and multidisciplinary peer-reviewed journal with a wide-ranging coverage, consolidating research activities in all areas of nanoscience and nanotechnology into a single and unique reference source. JNN is the first cross-disciplinary journal to publish original full research articles, rapid communications of important new scientific and technological findings, timely state-of-the-art reviews with author's photo and short biography, and current research news encompassing the fundamental and applied research in all disciplines of science, engineering and medicine.
  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • Terms & Conditions
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content